ELISAFE: Baseline characteristics from an observational study to evaluate real-world safety of eliglustat in patients with Gaucher disease

被引：0
|
作者：
Batsu, Isabela [1 ]
Accomando, Beverly [1 ]
Gaemers, Sebastiaan J. M. [2 ]
Sekulic, Davorka [1 ]
机构：
[1] Sanofi, Cambridge, MA USA
[2] Sanofi, Amsterdam, Netherlands
来源：
MOLECULAR GENETICS AND METABOLISM | 2022年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2021.11.036
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
21
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [21] Long-term safety outcomes of eliglustat in patients with Gaucher disease: Prospective, multi-center, observational, post authorization safety sub-registry study
    Giraldo, Pilar
    Batsu, Isabela
    Accomando, Beverly
    Gaemers, Sebastiaan J. M.
    Cil, Sefika Uslu
    Gouyette, Najat
    Scarpa, Maurizio
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [22] Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan
    Kuo, Ming-Chung
    Lin, Chien-Chin
    Lin, Hsuan-Yu
    Gau, Jyh-Pyng
    Wang, Ming-Chung
    Chang, Ming-Chih
    Chen, Tsung-Chih
    Yeh, Shih-Peng
    Chen, Yeu-Chin
    Huang, Cih-En
    Chiang, I-Ju
    Chung, Chu-Han
    Lee, Yee-Ming
    Ku, Fan-Chen
    Chang, Cheng-Shyong
    BLOOD, 2022, 140 : 9709 - 9710
  • [23] A REAL-WORLD OBSERVATIONAL STUDY TO EVALUATE DYSLIPIDEMIA MANAGEMENT IN PATIENTS WITH FIRST ACUTE CORONARY EVENT IN INDIA
    Tandayam, A.
    ATHEROSCLEROSIS, 2023, 379 : S101 - S101
  • [24] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
    Luis-Emilio García-Pérez
    Kristina S. Boye
    Myriam Rosilio
    Heike Jung
    Elke Heitmann
    Kirsi Norrbacka
    Marco Orsini Federici
    Raffaella Gentilella
    Bruno Guerci
    Francesco Giorgino
    Ulrich Aigner
    Hélène Sapin
    Diabetes Therapy, 2021, 12 : 1929 - 1946
  • [25] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS
    Garcia-Perez, L. E.
    Sapin, H.
    Norrbacka, K.
    Guerci, B.
    Giorgino, F.
    Aigner, U.
    Federici, Orsini M.
    Gentilella, R.
    Heitmann, E.
    Jung, H.
    Rosilio, M.
    Boye, K.
    VALUE IN HEALTH, 2019, 22 : S593 - S593
  • [26] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
    Garcia-Perez, Luis-Emilio
    Boye, Kristina S.
    Rosilio, Myriam
    Jung, Heike
    Heitmann, Elke
    Norrbacka, Kirsi
    Federici, Marco Orsini
    Gentilella, Raffaella
    Guerci, Bruno
    Giorgino, Francesco
    Aigner, Ulrich
    Sapin, Helene
    DIABETES THERAPY, 2021, 12 (07) : 1929 - 1946
  • [27] Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study
    Alten, Rieke
    Mariette, Xavier
    Galeazzi, Mauro
    Chartier, Melanie
    Rauch, Christiane
    Elbez, Yedid
    Lozenski, Karissa
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1692 - 1694
  • [28] ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3
    Giraldo, Pilar
    Gokcay, Gulden
    Batsu, Isabela
    Kissell, Julie
    Perichon, Maria G.
    Drelichman, Guillermo I.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 47 - 48
  • [29] Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
    Bergenstal, Richard M.
    Garrison, Louis P., Jr.
    Wintle, Matthew
    Blickensderfer, Amy
    Wade, Rolin
    Hou, Likun
    Miller, Lesley-Ann
    Scism-Bacon, Jamie
    Zagar, Anthony
    Misurski, Derek
    Herman, William H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 531 - 540
  • [30] Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)
    Titievsky, Lina
    Schuster, Tilman
    Wang, Ronnie
    Younus, Muhammad
    Palladino, Andrew
    Quazi, Kabir
    Wajnrajch, Michael P.
    Hernandez, Betina
    Becker, Pamela S.
    Weinreb, Neal J.
    Chambers, Christina
    Mansfield, Roy
    Taylor, Louise
    Tseng, Li-Jung
    Kaplan, Paige
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
12345